DE60325025D1 - Modulatoren des vanilloidrezeptors - Google Patents

Modulatoren des vanilloidrezeptors

Info

Publication number
DE60325025D1
DE60325025D1 DE60325025T DE60325025T DE60325025D1 DE 60325025 D1 DE60325025 D1 DE 60325025D1 DE 60325025 T DE60325025 T DE 60325025T DE 60325025 T DE60325025 T DE 60325025T DE 60325025 D1 DE60325025 D1 DE 60325025D1
Authority
DE
Germany
Prior art keywords
modulators
vanilloid receptor
vanilloid
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325025T
Other languages
English (en)
Inventor
Harshad Kantilal Rami
Mervyn Thompson
Gregor James Macdonald
Susan Marie Westaway
Darren Jason Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203677A external-priority patent/GB0203677D0/en
Priority claimed from GB0203673A external-priority patent/GB0203673D0/en
Priority claimed from GB0203680A external-priority patent/GB0203680D0/en
Priority claimed from GB0209032A external-priority patent/GB0209032D0/en
Priority claimed from GB0209003A external-priority patent/GB0209003D0/en
Priority claimed from GB0209035A external-priority patent/GB0209035D0/en
Priority claimed from GB0221318A external-priority patent/GB0221318D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60325025D1 publication Critical patent/DE60325025D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60325025T 2002-02-15 2003-02-13 Modulatoren des vanilloidrezeptors Expired - Lifetime DE60325025D1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0203677A GB0203677D0 (en) 2002-02-15 2002-02-15 Novel compounds
GB0203673A GB0203673D0 (en) 2002-02-15 2002-02-15 Novel compounds
GB0203680A GB0203680D0 (en) 2002-02-15 2002-02-15 Novel compounds
GB0209032A GB0209032D0 (en) 2002-04-19 2002-04-19 Novel compounds
GB0209003A GB0209003D0 (en) 2002-04-19 2002-04-19 Novel compounds
GB0209035A GB0209035D0 (en) 2002-04-19 2002-04-19 Novel compounds
GB0221318A GB0221318D0 (en) 2002-09-13 2002-09-13 Novel compounds
PCT/GB2003/000608 WO2003068749A1 (en) 2002-02-15 2003-02-13 Vanilloid receptor modulators

Publications (1)

Publication Number Publication Date
DE60325025D1 true DE60325025D1 (de) 2009-01-15

Family

ID=27739514

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325025T Expired - Lifetime DE60325025D1 (de) 2002-02-15 2003-02-13 Modulatoren des vanilloidrezeptors

Country Status (10)

Country Link
US (1) US7538121B2 (de)
EP (2) EP1480954B1 (de)
JP (1) JP2005526723A (de)
AR (1) AR038420A1 (de)
AT (1) ATE416168T1 (de)
AU (1) AU2003245773A1 (de)
DE (1) DE60325025D1 (de)
ES (1) ES2316777T3 (de)
TW (1) TW200403223A (de)
WO (1) WO2003068749A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345044T3 (es) 2002-02-01 2010-09-14 Euro-Celtique S.A. 2-piperazin-piridinas utiles para tratar el dolor.
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003241453A1 (en) 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
RS114804A (en) 2002-06-28 2006-12-15 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2004052846A1 (en) 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
WO2004052845A1 (en) * 2002-12-09 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
EP1575918A2 (de) * 2002-12-19 2005-09-21 Neurogen Corporation Substituierte biaryl-4-carbonsäure-arylamid-derivate als capsaicin-rezeptor-modulatoren
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
CA2526361C (en) 2003-05-20 2012-05-15 Ajinomoto Co., Inc. Amide derivative
PL1632477T3 (pl) 2003-06-12 2017-07-31 Astellas Pharma Inc. Pochodna benzamidu lub jej sól
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
ATE492278T1 (de) * 2003-07-23 2011-01-15 Synta Pharmaceuticals Corp Verbindungen gegen entzündungen und immun- relevante verwendungen
DK1867644T3 (da) 2003-07-24 2009-09-21 Euro Celtique Sa Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2005030753A2 (en) * 2003-09-22 2005-04-07 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
DE602004019294D1 (de) 2003-10-01 2009-03-19 Xention Ltd Tetrahydronaphthalin- und harnstoffderivate
JP4667384B2 (ja) 2003-10-07 2011-04-13 レノビス, インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
US7338950B2 (en) 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
EP1737414A2 (de) * 2004-01-23 2007-01-03 Amgen Inc. Vanilloid-rezeptor-liganden und ihre verwendung in der behandlung von entzündlichen und neuropathischen schmerzen
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7622579B2 (en) 2004-06-28 2009-11-24 Janssen Pharmaceutica Nv Hetero isonipecotic modulators of vanilloid VR1 receptor
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. 3−アミノベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤
KR101042490B1 (ko) 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(vr1)활성 저해제
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
CA2616079C (en) * 2005-07-22 2012-09-25 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
US7429605B2 (en) 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
JP4086895B2 (ja) 2005-12-28 2008-05-14 日本たばこ産業株式会社 3,4−ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
JP5306987B2 (ja) * 2006-03-16 2013-10-02 エボテック (ユーエス) インコーポレイテッド P2x7調節因子としてのビシクロへテロアリール化合物およびその使用
SG173320A1 (en) * 2006-03-27 2011-08-29 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
WO2008007211A1 (en) * 2006-07-11 2008-01-17 Pfizer Japan Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2069302B1 (de) 2006-09-15 2010-08-25 Pfizer Inc. Substituierte pyridylmethylbicyclocarboxyamidverbindungen
US8158650B2 (en) 2006-10-23 2012-04-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
US7964732B2 (en) 2006-11-17 2011-06-21 Pfizer Inc. Substituted bicyclocarboxyamide compounds
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
FR2911604B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
PE20081692A1 (es) * 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
MY148657A (en) * 2007-04-27 2013-05-15 Purdue Pharma Lp Trpv1 antagonists and uses thereof
NZ579820A (en) 2007-04-27 2011-01-28 Purdue Pharma Lp Therapeutic agents useful for treating pain
CA2709879A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Anilides and analogs as rho kinase inhibitors
EP2234487A4 (de) * 2007-12-19 2011-09-07 Scripps Research Inst Anilide und analoge als rho-kinasehemmer
EP2234618A4 (de) * 2007-12-21 2011-04-27 Scripps Research Inst Benzopyrane und analoga als rho-kinase-inhibitoren
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
JP5372138B2 (ja) 2008-04-18 2013-12-18 テウン ファーマシューティカル カンパニー,リミテッド 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2012525386A (ja) 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 疾患の治療のための二重機構阻害剤
RS56352B2 (sr) * 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
LT3156056T (lt) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Limited Farmacinės kompozicijos, apimančios sorbitano esterius
ME02609B (de) 2011-06-22 2017-06-20 Purdue Pharma Lp Trpv1-antagonisten mit dihydroxy-substituent und ihre verwendung
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
FR2984323B1 (fr) * 2011-12-16 2019-08-30 L'oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines, composition tinctoriale en comprenant, procedes et utilisations
FR2984318B1 (fr) 2011-12-16 2014-06-27 Oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP2827867B1 (de) 2012-03-19 2019-11-06 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit glycerinestern
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
EP2897592B1 (de) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
WO2016028971A1 (en) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
JP2017214290A (ja) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
WO2018085348A1 (en) * 2016-11-03 2018-05-11 Actavalon, Inc. Substituted quinolines and methods for treating cancer
US9840468B1 (en) 2016-12-30 2017-12-12 Aerie Pharmaceuticals, Inc. Methods for the preparation of 6-aminoisoquinoline
IT201700028127A1 (it) 2017-03-14 2018-09-14 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
MX2019011784A (es) 2017-03-31 2019-11-18 Aerie Pharmaceuticals Inc Compuestos de aril ciclopropil-amino-isoquinolinil amida.
FR3072286B1 (fr) 2017-10-13 2022-08-12 Oreal 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition
EP3761983A1 (de) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Dosierstrategie für aripiprazol
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN112574106B (zh) * 2020-11-11 2022-04-12 苏州康润医药有限公司 7-氨基-5-溴喹啉的合成方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
US3424761A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
JPS4824396B1 (de) * 1970-09-09 1973-07-20
DE2502588A1 (de) 1975-01-23 1976-07-29 Troponwerke Dinklage & Co Basisch substituierte derivate des 7-amino-2-chinolons, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4456604A (en) 1981-05-26 1984-06-26 Merck & Co., Inc. 1-(3-Halo-2-pyridinyl) piperazine
EP0130795B1 (de) 1983-07-05 1988-11-23 Pfizer Inc. Karbonsäure-Derivate verwendbar bei der Verhütung der Zersetzung von Knorpeln
US4803162A (en) * 1984-05-15 1989-02-07 Fluorodiagnostic Limited Partners Composition, article and process for detecting a microorganism
EP0266949B1 (de) 1986-10-28 1990-11-28 Smith Kline & French Laboratories Limited Tetrahydroisochinolin-2-yl-Derivate von Carbonsäuren als Thromboxan A2-Antagonisten
DE3701277A1 (de) * 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE68918991T2 (de) 1988-06-17 1995-04-27 Procter & Gamble Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
AU9079491A (en) 1990-11-27 1992-06-25 Procter & Gamble Company, The Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5342851A (en) 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
CN1104418C (zh) 1994-06-15 2003-04-02 大塚制药株式会社 苯并杂环衍生物
GB9416972D0 (en) 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
EP0832069B1 (de) * 1995-06-07 2003-03-05 Pfizer Inc. Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
TW280869B (en) 1995-07-17 1996-07-11 Philips Electronics Nv IDDQ-testing of bias generator circuit
EE9700207A (et) 1995-08-10 1998-02-16 Astra Aktiebolag Teraapias kasutatavad bitsüklilised amidiini derivaadid
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GB9605883D0 (en) 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
EP0891355A1 (de) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitreon von farnesylprotein-transferase
JP2000510137A (ja) 1996-05-11 2000-08-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンd3受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体
AR008234A1 (es) * 1996-06-17 1999-12-29 Smithkline Beecham Plc Derivados de benzamidas, procedimiento para su preparacion, composiciones farmaceuticas y su uso para la preparacion de un medicamento
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
KR100568654B1 (ko) * 1997-03-18 2006-04-07 스미스클라인비이참피이엘시이 치환된 이소퀴놀린 유도체 및 진경제로서의 그의 용도
AUPO622597A0 (en) * 1997-04-15 1997-05-08 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
CN1260781A (zh) 1997-04-18 2000-07-19 史密丝克莱恩比彻姆有限公司 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物
JP2001508402A (ja) * 1997-06-13 2001-06-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換ベンズアミド誘導体およびそれらの抗痙攣薬としての使用
WO1999021836A1 (en) * 1997-10-24 1999-05-06 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
WO2000006085A2 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Compounds and methods
GB9817424D0 (en) 1998-08-11 1998-10-07 Smithkline Beecham Plc Novel compounds
ATE316969T1 (de) 1998-10-08 2006-02-15 Smithkline Beecham Plc Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
DE60023128T2 (de) 1999-05-12 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
NZ515894A (en) * 1999-06-02 2003-09-26 Nps Pharma Inc Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1218336A2 (de) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagonisten des melanin-konzentrierenden hormons
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2002241274A (ja) * 2000-04-28 2002-08-28 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
CN1324845A (zh) 2000-05-24 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人蛋白合成起始因子2β亚单位16.5和编码这种多肽的多核苷酸
NZ523526A (en) * 2000-07-20 2004-10-29 Neurogen Corp Diaryl piperazines as capsaicin receptor ligands
WO2002016317A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
US20030153596A1 (en) 2000-08-21 2003-08-14 Suh Young Ger Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002016318A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
CA2452606C (en) * 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
JP4408618B2 (ja) * 2001-10-25 2010-02-03 武田薬品工業株式会社 キノリン化合物
JP2005518365A (ja) * 2001-11-27 2005-06-23 メルク エンド カムパニー インコーポレーテッド 4−アミノキノリン化合物
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
WO2003070247A1 (en) * 2002-02-20 2003-08-28 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Also Published As

Publication number Publication date
AU2003245773A1 (en) 2003-09-04
ES2316777T3 (es) 2009-04-16
WO2003068749A1 (en) 2003-08-21
US7538121B2 (en) 2009-05-26
JP2005526723A (ja) 2005-09-08
EP2033953A1 (de) 2009-03-11
AR038420A1 (es) 2005-01-12
US20060142333A1 (en) 2006-06-29
TW200403223A (en) 2004-03-01
EP1480954B1 (de) 2008-12-03
ATE416168T1 (de) 2008-12-15
EP1480954A1 (de) 2004-12-01

Similar Documents

Publication Publication Date Title
ATE416168T1 (de) Modulatoren des vanilloidrezeptors
DK1521733T3 (da) Modulatorer af glucocorticoid receptoren
ATE533743T1 (de) Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
NO20023283D0 (no) Flammestopper
DK1569712T3 (da) Forbindelsesindretning
ATE544762T1 (de) Calcium rezeptor modulatoren
DE50311534D1 (de) Gewebeband-einrichtung
NO20044046L (no) Substituerte hydroksyetylaminer
ATE456558T1 (de) Gabanerge modulatoren
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
ATE428685T1 (de) Aminosubstituierte ethylaminoagonisten des beta2- adrenergen rezeptors
ATE356124T1 (de) Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE50305140D1 (de) Zerstäubungsanordnung
NO20023357D0 (no) Blanding
DE50313548D1 (de) Zerstäubungsanordnung
DE60331207D1 (de) Flüssigkeitsrakete
NO20053156D0 (no) Anvendelse av ostrogen reseptor alfa modulatorer for behandling av multippel sklerose.
DE10394144D2 (de) Duschvorrichtung
ATA5002002A (de) Vibrator
FR2843451B1 (fr) Fronde du type lance-pierres
ATE350379T1 (de) Substituierte benzdioxepine
NO20044364L (no) Hydroksykarbamimidoyl-2-hydroksy-benzensulfonamidderivat-krystaller
DE50300775D1 (de) Zweipunkt-modulatoranordnung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition